A865of the Mexican population, that is the reason why the institution must consider alternatives that bring not only effectiveness, instead "value for money" due to cost cuttings and containment issues experienced during the last years. Methods: The cost model considered population covered by the Mexican Institute of Social Security (IMSS), in this sense the target population (base case scenario) was chosen based on those patients with DT1 diagnosed and treated, in order to model the budget impact with and without the intervention. We conducted a pragmatic literature review and treatment comparison to find out hypoglycemic events frequency (event rate and event/patient/year). The time horizon was 12 months and the model only considered the medical direct costs. Results: After split the population (based on coverage pop at IMSS, very uncontrolled patients, diagnosed and treated), the cost model considered 40,439 DT1 patients. Without intervention, it was modelled 15,468 hypoglycemic events ($6.9 million dollars. Every treatment scenario was weighted according to literature review inputs). With intervention on base case scenario and best case (77.81% and 90.24% reduction on severe events) the frequency of severe events were 3,432 and 1,509, respectively (which it means a total costs that oscillate between $1.5 million and $675k dollars) ConClusions: The savings due to intervention (SAP) were described between $5.4 to 6.2 million of dollars. The analysis just account for those avoided acute events, we did not simulate those mid-term or long-term complications avoided neither indirect costs, items that could increase the effect size and costs savings due to SAP therapy on very uncontrolled DT1 patients.
El 19,5% (n= 124) de pacientes habían egresado del programa al final de periodo de observación. Las causas de egreso fueron: mejoría a TFG > 60 ml/min/año (40,3%), muerte (29,0%), ingreso a diálisis (12,1%), suspensión voluntaria (5,7%), otros (12,9%). Seguimos a los pacientes 31582 pacientes-mes, equivalente a 2631 pacientes-año y la mortalidad fue 0.0137 muertes por paciente-año en el programa. ConClusiones: Los meses evitados de diálisis por paciente en ERC 5 son 11. Una proporción sustancial de pacientes alcanzaron las metas de progresión de ERC. La principal causa de egreso del programa fue por mejoría de la TFG. PUK2 CliniCal Benefits of immUnosUPPression theraPy in renal trasPlant Patients. systematiC review and meta-analysis
upper extremity of these elderly patients with very fair skin. The preferred treatment was physical destruction of the lesions instead of noninvasive topical therapy.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.